Latest news

• Biogen’s tofersen shows promise in slowing down ALS

  tofersen in SOD1-ALS patients and further demonstrate the potential of ASOs to target the genetic driver of disease,” said Michael Ehlers, executive vice president, research and development at Biogen. ... Michael Ehlers recently said the company

• Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

  We believe we have a path forward and we are working to lift the hold as quickly as possible,” said Biogen’s head of R&D Michael Ehlers on the call.

• Biogen pays $590m for Pfizer cognition drug

  When cognition is impaired, you lose the ability to make sense of the world,” said Michael Ehlers, Biogen’s head of R&D.

• Biogen cuts $217m deal for Karyopharm neurology drug

  On a conference call to discuss Biogen’s fourth quarter results, R&D head Michael Ehlers said that KPT-350 is a “first-in-class phase I ready investigational oral compound

• Pfizer drops neuroscience R&D, cutting 300 jobs

  enzyme. Pfizer’s decision comes after its former head of neuroscience R&D Michael Ehlers left to take up the top R&D role at Biogen in 2016.